VEGF, anti-VEGF and diseases;VEGF, anti-VEGF et pathologies

Bulletin de l'Academie Nationale de Medecine

Volumn 192, Issue 2, 2008, Pages 289-302

  Corvol, Pierre ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b Centre de Recherche Interdisciplinaire en Biologie   (France)

Author keywords

Diabetic retinopathy; Macular degeneration; Neoplasms; Neovascularization; Vascular endothelial growth factors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL; CELL HYPOXIA; DIABETIC RETINOPATHY; DRUG ANTAGONISM; EMBRYO DEVELOPMENT; HUMAN; INFLAMMATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA DEGENERATION; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DIABETIC RETINOPATHY; EMBRYONIC DEVELOPMENT; HUMANS; INFLAMMATION; MACULAR DEGENERATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55949104446     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)32831-6     Document Type: Conference Paper

References (16)

1. CARMELIET P. -Angiogenesis in life, disease and medicine. Nature, 2005, 438, 932-936.
2. [2] FERRARA N. -Vascular endothelial growth factor : basic science and clinical progress. Endocr. Rev., 2004, 25, 581-611. (Pubitemid 39099316)
3. [3] KOWANETZ M., FERRARA N. -Vascular endothelial growth factor signaling pathways : therapeutic perspective. Clin. Cancer Res., 2006, 12, 5018-15012 (Pubitemid 44453326)
4. [4] AUTIERO M., DE SMET F., CLAES F., CARMELIET P. -Role of neural guidance signals in blood vessel navigation. Cardiovasc. Res., 2005, 65, 629-638. (Pubitemid 40138983)
5. LONSER R.R., GLENN G.M., WALTHER M., et al. -Von Hippel-Lindau disease. Lancet, 2003, 361, 2059-2067.
6. FOLKMAN J. -Tumor angiogenesis : therapeutic implications. N. Engl. J. Med., 1971, 285, 1182-1186.
7. CARMELIET P., JAIN R.K. -Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-257.
8. FAVIER J., PLOUIN P-F., CORVOL P., GASC J-M. -Angiogenesis and vascular architecture in pheochromocytomas : distinctive traits in malignant tumors. Am. J. Pathol, 2002, 161, 1235-1246.
9. SHWELKI D., ITIN A., SOFFER D., KESHET E. -Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992, 359, 843-845.
10. [10] GASPARINI G., LONGO R., TOI M., FERRARA N. -Angiogenic inhibitors : a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol, 2005, 2, 562-577. (Pubitemid 41721816)
11. WARREN R.S., YUAN H., MALT M.R., GILLETT N.A., FERRARA N. -Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastatis. J. Clin. Invest., 1995, 95, 1789-1797.
12. [12] YANG J.G., HAWORTH L., SHERRY R.M., et al. -A radomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med., 2003, 349, 427-434. (Pubitemid 36910021)
13. [13] HURWITZ H., FEHRENBACHER L., NOVOTNY W., et al. -Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350, 2335-2342. (Pubitemid 38702844)
14. AZIZI M., CHEDID A., OUDARD S. -Home blood-pressure monitoring in patients receiving sunitinib. N. Engl. J. Med., 2008, 358, 95-97.
15. [15] JAIN R.K. -Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy. Science, 2005, 307, 58-62. (Pubitemid 40093472)
16. [16] SHOJAEI F., FERRARA N.-Angiogenesis to treat cancer and intraocular neovascular disorders. Lab. Invest., 2007, 87, 227-230. (Pubitemid 46353946)